ALYREF and pancreatic neoplasm: The intensity of the immunostaining with anti-ALY was reduced in colon, stomach, thyroid, testis and pancreas tumor samples with a cytoplasmic and lower signal than the control samples in almost 50% of the tumors analyzed (Figure 4B).